Adial Pharmaceuticals, Inc. 8-K Filing – Important Updates on January 8, 2025

Here are the key pieces of information extracted from the provided section of the financial report:

1. Document Type and Date:

• The document is an 8-K filing, which is typically used to report significant events that shareholders should be aware of.
• The filing date is January 8, 2025.

2. Entity Information:

• Company Name: Adial Pharmaceuticals, Inc.
• CIK Number: 0001513525 (Central Index Key - a unique identifier for companies filing with the SEC).
• IRS Employer Identification Number: 82-3074668.
• Address: 4870 Sadler Road Ste 300, Glen Allen, VA 23060.
• Phone Number: 804-487-8196.

3. Stock Information:

• Common Stock Ticker: ADIL.
• Exchange: NASDAQ.

4. Reporting Period:

• The reporting period is a single day, with both the start and end date being January 8, 2025.

5. Units of Measure:

• Financial data is reported in USD (United States Dollars).
• There are also references to shares as a unit of measure, suggesting that the report may include information on stock performance or share metrics.

6. Schema Reference:

• The report references a schema file named "adil-20250108.xsd," indicating that it follows a specific structured format for data presentation.

Insights:

• The filing is likely to contain important updates or disclosures relevant to shareholders or potential investors, given the nature of the 8-K form.
• Adial Pharmaceuticals appears to be actively communicating with its investors and regulators, as indicated by the timely filing of this report.
• The use of specific XML and XBRL formats suggests a focus on structured data for ease of analysis and integration with financial systems.

This context can be particularly relevant for investors looking to understand the current status and recent developments of Adial Pharmaceuticals, Inc.